Glucotrack Wins New Funding for Continuous Blood Glucose Monitor

Glucotrack Inc. has secured $4 million from leading shareholder John Ballantyne to help fund its first in human clinical trial.
 
“This year, we have made significant progress in the development of our continuous blood glucose monitor (CBGM) technology. This funding, by longstanding investor John Ballantyne, provides increased financial flexibility for the company as we embark on human clinical trials for this less burdensome approach to glucose monitoring,” Glucotrack CEO Paul V. Goode, Ph.D., said.

---

READ MORE: GlucoTrack Moves Toward Human Trials of Implantable Continuous Blood Glucose Monitor

---

 
“Since my initial investment, the company has undergone a significant evolution in its technology and focus. This has accelerated development of the innovative CBGM which has the potential to be disruptive in a large and growing diabetes market,” Ballantyne commented. “I remain confident that the company and its leadership team are well-positioned to deliver strong clinical value to the diabetes community and meaningful value to the shareholder community.” 
 
Glucotrack Inc. desigs, develops, and commercializes technologies for people with diabetes. The company is currently developing a long-term implantable continuous blood glucose monitoring system for people living with diabetes.Glucotrack’s CBGM is a long-term, implantable system that continually measures blood glucose levels with a sensor longevity of more than years, no on-body wearable component, and with minimal calibration.